-
公开(公告)号：US06331390B1
公开(公告)日：2001-12-18
申请号：US08497214
申请日：1995-06-30
IPC分类号： C12Q168
CPC分类号： C12N15/8509 , A01K2217/075 , A01K2227/105 , A01K2267/0331 , C07K14/4702 , C07K14/4738 , C07K16/18 , C12N9/12 , C12N2830/007 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , G01N33/57496 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).
摘要翻译： 本发明涉及一种新型的细胞周期调控蛋白家族（“CCR-蛋白”）在真核细胞特别是哺乳动物细胞中的发现。 如本文所述，该蛋白家族的特征在于四种锚蛋白重复序列和结合细胞周期蛋白依赖性激酶（CDK）的能力。 家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可以起到细胞周期进程的抑制剂的作用，因此可以最终形成细胞生长。 因此，类似于p21对p53检查点的作用，受试者CCR-蛋白质可以与细胞周期调节蛋白，视网膜母细胞瘤（RB）协调地起作用。
-
公开(公告)号：US5968821A
公开(公告)日：1999-10-19
申请号：US893274
申请日：1997-07-15
IPC分类号： A61K31/70 , A61K48/00 , C07H21/04 , C07K14/47 , C07K16/00 , C07K16/18 , C12N5/06 , C12N9/12 , C12N15/85 , C12N15/87 , C12P21/02 , C12P21/04 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , C12N15/00
CPC分类号： C07K14/4702 , A01K67/0276 , C07K14/4738 , C07K16/18 , C12N15/8509 , C12N9/12 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , G01N33/5011 , G01N33/574 , G01N33/57496 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , A61K48/00 , C07K2319/23 , C12N2799/022 , C12N2800/30 , G01N2333/4736 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
-
3.发明申请公开(公告)号：US20090170098A1
公开(公告)日：2009-07-02
申请号：US12195135
申请日：2008-08-20
IPC分类号： C12Q1/68
CPC分类号： G01N33/5011 , C07K2319/23 , G01N33/574 , G01N2333/4736 , Y10S435/81
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.
摘要翻译： 本发明涉及在真核细胞，特别是哺乳动物细胞中发现一系列细胞周期调节蛋白（“CCR-蛋白”）。 如本文所述，该蛋白质家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可用作细胞周期进程的抑制剂，因此最终 的细胞生长。 本发明包括针对这种CCR-蛋白的抗体。 本发明涉及用于检测包含针对p16蛋白的抗体的细胞周期蛋白依赖性激酶抑制剂p16基因表达水平的试剂盒。
-
公开(公告)号：US07550561B1
公开(公告)日：2009-06-23
申请号：US08227371
申请日：1994-04-14
IPC分类号： C12Q1/68 , C12P21/04 , C07K14/435
CPC分类号： C07K14/4738 , C07K2319/23
摘要： The present invention relates to the discovery in eukaryotic cells, particularly human cells, a novel polypeptide of 16 kDa (hereinafter “p16INK4” or “p16”) can function as an inhibitor of cell cycle progression, and therefore ultimately of cell growth, and that similar to the role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb).
摘要翻译： 本发明涉及在真核细胞特别是人类细胞中发现16kDa的新多肽（以下称为“p16INK4”或“p16”）可以起细胞周期进程的抑制剂的作用，因此最终可以作为细胞生长，而且 类似于p21和p53的作用，p16蛋白可能与细胞周期调节蛋白，视网膜母细胞瘤（Rb）协调起作用。
-
公开(公告)号：US6043030A
公开(公告)日：2000-03-28
申请号：US581918
申请日：1996-01-02
CPC分类号： C12N15/8509 , A01K67/0276 , C07K14/4702 , C07K14/4738 , C07K16/18 , C12N9/12 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , G01N33/57496 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , C12Q2600/154 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).
摘要翻译： 本发明涉及一种新型的细胞周期调控蛋白家族（“CCR-蛋白”）在真核细胞特别是哺乳动物细胞中的发现。 如本文所述，该蛋白家族的特征在于四种锚蛋白重复序列和结合细胞周期蛋白依赖性激酶（CDK）的能力。 家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可以起到细胞周期进程的抑制剂的作用，因此可以最终形成细胞生长。 因此，类似于p21对p53检查点的作用，受试者CCR-蛋白质可以与细胞周期调节蛋白，视网膜母细胞瘤（RB）协调地起作用。
-
公开(公告)号：US5962316A
公开(公告)日：1999-10-05
申请号：US306511
申请日：1994-09-14
IPC分类号： A61K31/70 , A61K48/00 , C07H21/04 , C07K14/47 , C07K16/00 , C07K16/18 , C12N5/06 , C12N9/12 , C12N15/85 , C12N15/87 , C12P21/02 , C12P21/04 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , C12N15/00
CPC分类号： C07K14/4702 , A01K67/0276 , C07K14/4738 , C07K16/18 , C12N15/8509 , C12N9/12 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , G01N33/5011 , G01N33/574 , G01N33/57496 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , A61K48/00 , C07K2319/23 , C12N2799/022 , C12N2800/30 , G01N2333/4736 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
-
7.发明授权Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression 失效用于检测细胞周期蛋白依赖性激酶抑制剂P16基因表达水平的试剂盒公开(公告)号：US07691632B2
公开(公告)日：2010-04-06
申请号：US12195135
申请日：2008-08-20
IPC分类号： C07K16/00
CPC分类号： G01N33/5011 , C07K2319/23 , G01N33/574 , G01N2333/4736 , Y10S435/81
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.
摘要翻译： 本发明涉及在真核细胞，特别是哺乳动物细胞中发现一系列细胞周期调节蛋白（“CCR-蛋白”）。 如本文所述，该蛋白质家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可用作细胞周期进程的抑制剂，因此最终 的细胞生长。 本发明包括针对这种CCR-蛋白的抗体。 本发明涉及用于检测包含针对p16蛋白的抗体的细胞周期蛋白依赖性激酶抑制剂p16基因表达水平的试剂盒。
-
公开(公告)号：US07425617B2
公开(公告)日：2008-09-16
申请号：US09016869
申请日：1998-01-30
IPC分类号： C07K16/00
CPC分类号： C07K14/4702 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , A61K48/00 , C07K14/4738 , C07K16/18 , C07K2319/23 , C12N9/12 , C12N15/8509 , C12N2799/022 , C12N2800/30 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , G01N33/5011 , G01N33/574 , G01N33/57496 , G01N2333/4736 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins.
摘要翻译： 本发明涉及在真核细胞，特别是哺乳动物细胞中发现一系列细胞周期调节蛋白（“CCR-蛋白”）。 如本文所述，该蛋白质家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可用作细胞周期进程的抑制剂，因此最终 的细胞生长。 本发明包括针对这种CCR-蛋白的抗体。
-
公开(公告)号：US06486131B2
公开(公告)日：2002-11-26
申请号：US09016750
申请日：1998-01-30
IPC分类号： A61K3170
CPC分类号： C07K14/4702 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , A61K48/00 , C07K14/4738 , C07K16/18 , C07K2319/23 , C12N9/12 , C12N15/8509 , C12N2799/022 , C12N2800/30 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , G01N33/5011 , G01N33/574 , G01N33/57496 , G01N2333/4736 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
摘要翻译： 本发明涉及一种新型的细胞周期调控蛋白家族（“CCR-蛋白”）在真核细胞特别是哺乳动物细胞中的发现。 如本文所述，该蛋白质家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可用作细胞周期进程的抑制剂，因此最终 的细胞生长。 因此，类似于p21对p53检查点的作用，受试者CCR-蛋白质可以与细胞周期调节蛋白，视网膜母细胞瘤（RB）协调地起作用。 此外，CCR-蛋白家族包括表观分子量为13.5kDa的蛋白质（以下称为“p13.5”）。 p13.5的假定作用，如p16和p15，是调节细胞周期。
-
公开(公告)号：US5889169A
公开(公告)日：1999-03-30
申请号：US248812
申请日：1994-05-25
申请人： David H. Beach , Douglas J. Demetrick , Manuel Serrano , Gregory J. Hannon , Dawn E. Quelle , Charles J. Sherr
发明人： David H. Beach , Douglas J. Demetrick , Manuel Serrano , Gregory J. Hannon , Dawn E. Quelle , Charles J. Sherr
CPC分类号： C12N15/8509 , C07K14/4702 , C07K14/4738 , C07K16/18 , C12N9/12 , C12Q1/6811 , C12Q1/6883 , C12Q1/6886 , G01N33/57496 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0331 , C12Q2600/136 , G01N2333/4739
摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, these family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa (hereinafter "p16.sup.INK4 " OR "p16") and which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth, and that similar to role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16, is in the regulation of the cell-cycle.
摘要翻译： 本发明涉及一种新型的细胞周期调控蛋白家族（“CCR-蛋白”）在真核细胞特别是哺乳动物细胞中的发现。 如本文所述，这些蛋白质家族包括具有16kDa表观分子量（以下称为“p16INK4”OR“p16”）的多肽，其可用作细胞周期进程的抑制剂，因此可以最终作为细胞生长，以及 与p21和p53的作用相似，p16蛋白可能与细胞周期调节蛋白，视网膜母细胞瘤（Rb）配位起作用。 此外，CCR-蛋白家族包括表观分子量为13.5kDa的蛋白质（以下称为“p13.5”）。 p13.5的假定作用，如p16，是调节细胞周期。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.041 秒)
